Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Publication | Open Access

DOI Full Paper Access

585

Citations

References

2017

Year

Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley,

The Lancet Oncology

Paclitaxel–carboplatin ChemotherapySecondary CytoreductionMedicineMetronomic TherapyPharmacologyGynecologyPlatinum-sensitive Ovarian CancerCancer TreatmentOncologyGynecology OncologyMolecular OncologyOvarian Cancer